Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

"Talimogene laherparepvec (HSV-1 \[strain JS1\]/ICP34.5-/ICP47-/hGM-CSF) is an oncolytic immunotherapy, formerly known as OncoVEXGM-CSF, an immune-enhanced, oncolytic herpes simplex virus type 1 (HSV-1)~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"

"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given.~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"

Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care